The weekly litigation news digest is live. Subscribe now

IP Verse

Sustained-Release Dosage Forms Of Ruxolitinib - EP2919766

The patent EP2919766 was granted to Incyte on May 26, 2021. The application was filed on Nov 14, 2013 under application number EP13798840A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2919766

INCYTE
Application Number
EP13798840A
Filing Date
Nov 14, 2013
Status
Granted And Under Opposition
Apr 23, 2021
Publication Date
May 26, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ALFRED E TIEFENBACHERFeb 28, 2022HAMM & WITTKOPPADMISSIBLE
STADA ARZNEIMITTELFeb 28, 2022HAMM & WITTKOPPADMISSIBLE
MAIWALDFeb 25, 2022MAIWALDADMISSIBLE
TEVA PHARMACEUTICALSFeb 25, 2022D YOUNGADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2014016396
INTERNATIONAL-SEARCH-REPORTUS2009088410
OPPOSITIONUS2009088410
OPPOSITIONUS5403593
OPPOSITIONUS7153845
OPPOSITIONWO2014016396
OPPOSITIONWO2014078486

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents